New research out of #London, Ont.’s #WesternUniversity is shedding light on a potential cure for #ALS, in which the targeting of the interaction between two proteins can halt or fully reverse the disease’s progression.
According to a news release from Western University on Monday, a team of researchers, led by Dr. #MichaelStrong, have discovered a potential path toward a cure for #AmyotrophicLateralSclerosis, also known as ALS
Treatment of #Parkinsons, #Huntingtons, #ALS, and other #brain diseases depends on reliable detection—especially in those who don’t even know they’re at risk. An innovative scratch-and-sniff test can help.
@StevenvdV82. For anyone reading this thread, perhaps this #UCSF information about #ALS (and statistical overlap with #FTD) is helpful. According to the #MAC (Memory and Aging Center), "While estimates vary, it is now believed that approximately 20% of ALS patients also have the signs and symptoms of frontotemporal dementia." https://memory.ucsf.edu/dementia/amyotrophic-lateral-sclerosis
Good day all! I'm pretty busy just at the moment, but I thought audiophiles (as well as regular people) would find this an interesting read or listen. Steven told me about it.
"He spent his life building a $1 million stereo. The real cost was unfathomable.
Ken Fritz turned his home into an audiophile’s dream — the world’s greatest hi-fi. What would it mean in the end?"
Study identifies mitochondrial dysfunction as cause of long-COVID fatigue.
"Researchers from Amsterdam UMC and Vrije Universiteit Amsterdam (VU) have discovered that the persistent fatigue in patients with long-COVID has a biological cause, namely mitochondria in muscle cells that produce less energy than in healthy patients. The results of the study were published today in Nature Communications."
We said goodbye to one of our beloved dogs this week after a 2 year journey with degenerative myelopathy. He would have been 12 in February. My heart is broken. 💔
Antibody/Gene Therapy Biotech Gains $138 Million in Early Funds
A developer of synthetic antibodies for neurodegenerative disorders delivered like gene therapies is raising €129 million ($US 138 million) in its first venture funding round.